284 related articles for article (PubMed ID: 36793668)
1. The Current Role of Disease-modifying Osteoarthritis Drugs.
Rodriguez-Merchan EC
Arch Bone Jt Surg; 2023; 11(1):11-22. PubMed ID: 36793668
[TBL] [Abstract][Full Text] [Related]
2. Lorecivivint, a Novel Intraarticular CDC-like Kinase 2 and Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A Inhibitor and Wnt Pathway Modulator for the Treatment of Knee Osteoarthritis: A Phase II Randomized Trial.
Yazici Y; McAlindon TE; Gibofsky A; Lane NE; Clauw D; Jones M; Bergfeld J; Swearingen CJ; DiFrancesco A; Simsek I; Tambiah J; Hochberg MC
Arthritis Rheumatol; 2020 Oct; 72(10):1694-1706. PubMed ID: 32432388
[TBL] [Abstract][Full Text] [Related]
3. Long-Term Safety and Efficacy of Subcutaneous Tanezumab Versus Nonsteroidal Antiinflammatory Drugs for Hip or Knee Osteoarthritis: A Randomized Trial.
Hochberg MC; Carrino JA; Schnitzer TJ; Guermazi A; Walsh DA; White A; Nakajo S; Fountaine RJ; Hickman A; Pixton G; Viktrup L; Brown MT; West CR; Verburg KM
Arthritis Rheumatol; 2021 Jul; 73(7):1167-1177. PubMed ID: 33538113
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of tanezumab added on to diclofenac sustained release in patients with knee or hip osteoarthritis: a double-blind, placebo-controlled, parallel-group, multicentre phase III randomised clinical trial.
Balanescu AR; Feist E; Wolfram G; Davignon I; Smith MD; Brown MT; West CR
Ann Rheum Dis; 2014 Sep; 73(9):1665-72. PubMed ID: 23852695
[TBL] [Abstract][Full Text] [Related]
5. Intra-articular viscosupplementation with hylan g-f 20 to treat osteoarthritis of the knee: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2005; 5(10):1-66. PubMed ID: 23074461
[TBL] [Abstract][Full Text] [Related]
6. Lorecivivint, an intra-articular potential disease-modifying osteoarthritis drug.
Sabha M; Siaton BC; Hochberg MC
Expert Opin Investig Drugs; 2020 Dec; 29(12):1339-1346. PubMed ID: 33096010
[No Abstract] [Full Text] [Related]
7. Effectiveness of Various Dosages and Administration Methods of Tanezumab for the Treatment of Pain in Knee and Hip Osteoarthritis: a Network Meta-Analysis.
Cai YZ; Nie LY; Ruan JQ; Zhao K
Clin Ther; 2021 Dec; 43(12):2116-2126. PubMed ID: 34819241
[TBL] [Abstract][Full Text] [Related]
8. Modulation of the Wnt pathway through inhibition of CLK2 and DYRK1A by lorecivivint as a novel, potentially disease-modifying approach for knee osteoarthritis treatment.
Deshmukh V; O'Green AL; Bossard C; Seo T; Lamangan L; Ibanez M; Ghias A; Lai C; Do L; Cho S; Cahiwat J; Chiu K; Pedraza M; Anderson S; Harris R; Dellamary L; Kc S; Barroga C; Melchior B; Tam B; Kennedy S; Tambiah J; Hood J; Yazici Y
Osteoarthritis Cartilage; 2019 Sep; 27(9):1347-1360. PubMed ID: 31132406
[TBL] [Abstract][Full Text] [Related]
9. A novel Wnt pathway inhibitor, SM04690, for the treatment of moderate to severe osteoarthritis of the knee: results of a 24-week, randomized, controlled, phase 1 study.
Yazici Y; McAlindon TE; Fleischmann R; Gibofsky A; Lane NE; Kivitz AJ; Skrepnik N; Armas E; Swearingen CJ; DiFrancesco A; Tambiah JRS; Hood J; Hochberg MC
Osteoarthritis Cartilage; 2017 Oct; 25(10):1598-1606. PubMed ID: 28711582
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of intravenous tanezumab for the symptomatic treatment of osteoarthritis: 2 randomized controlled trials versus naproxen.
Ekman EF; Gimbel JS; Bello AE; Smith MD; Keller DS; Annis KM; Brown MT; West CR; Verburg KM
J Rheumatol; 2014 Nov; 41(11):2249-59. PubMed ID: 25274899
[TBL] [Abstract][Full Text] [Related]
11. A small-molecule inhibitor of the Wnt pathway (SM04690) as a potential disease modifying agent for the treatment of osteoarthritis of the knee.
Deshmukh V; Hu H; Barroga C; Bossard C; Kc S; Dellamary L; Stewart J; Chiu K; Ibanez M; Pedraza M; Seo T; Do L; Cho S; Cahiwat J; Tam B; Tambiah JRS; Hood J; Lane NE; Yazici Y
Osteoarthritis Cartilage; 2018 Jan; 26(1):18-27. PubMed ID: 28888902
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of tanezumab monotherapy or combined with non-steroidal anti-inflammatory drugs in the treatment of knee or hip osteoarthritis pain.
Schnitzer TJ; Ekman EF; Spierings EL; Greenberg HS; Smith MD; Brown MT; West CR; Verburg KM
Ann Rheum Dis; 2015 Jun; 74(6):1202-11. PubMed ID: 24625625
[TBL] [Abstract][Full Text] [Related]
13. Effect of Tanezumab on Joint Pain, Physical Function, and Patient Global Assessment of Osteoarthritis Among Patients With Osteoarthritis of the Hip or Knee: A Randomized Clinical Trial.
Schnitzer TJ; Easton R; Pang S; Levinson DJ; Pixton G; Viktrup L; Davignon I; Brown MT; West CR; Verburg KM
JAMA; 2019 Jul; 322(1):37-48. PubMed ID: 31265100
[TBL] [Abstract][Full Text] [Related]
14. Subcutaneous tanezumab for osteoarthritis of the hip or knee: efficacy and safety results from a 24-week randomised phase III study with a 24-week follow-up period.
Berenbaum F; Blanco FJ; Guermazi A; Miki K; Yamabe T; Viktrup L; Junor R; Carey W; Brown MT; West CR; Verburg KM
Ann Rheum Dis; 2020 Jun; 79(6):800-810. PubMed ID: 32234715
[TBL] [Abstract][Full Text] [Related]
15. Recommendations for the use of new methods to assess the efficacy of disease-modifying drugs in the treatment of osteoarthritis.
Abadie E; Ethgen D; Avouac B; Bouvenot G; Branco J; Bruyere O; Calvo G; Devogelaer JP; Dreiser RL; Herrero-Beaumont G; Kahan A; Kreutz G; Laslop A; Lemmel EM; Nuki G; Van De Putte L; Vanhaelst L; Reginster JY;
Osteoarthritis Cartilage; 2004 Apr; 12(4):263-8. PubMed ID: 15023377
[TBL] [Abstract][Full Text] [Related]
16. Based on minimal clinically important difference values, a moderate dose of tanezumab may be a better option for treating hip or knee osteoarthritis: a meta-analysis of randomized controlled trials.
Zhao D; Luo MH; Pan JK; Zeng LF; Liang GH; Han YH; Liu J; Yang WY
Ther Adv Musculoskelet Dis; 2022; 14():1759720X211067639. PubMed ID: 35069811
[TBL] [Abstract][Full Text] [Related]
17. When Is Osteonecrosis Not Osteonecrosis?: Adjudication of Reported Serious Adverse Joint Events in the Tanezumab Clinical Development Program.
Hochberg MC; Tive LA; Abramson SB; Vignon E; Verburg KM; West CR; Smith MD; Hungerford DS
Arthritis Rheumatol; 2016 Feb; 68(2):382-91. PubMed ID: 26554876
[TBL] [Abstract][Full Text] [Related]
18. Observed efficacy and clinically important improvements in participants with osteoarthritis treated with subcutaneous tanezumab: results from a 56-week randomized NSAID-controlled study.
Neogi T; Hunter DJ; Churchill M; Shirinsky I; White A; Guermazi A; Omata M; Fountaine RJ; Pixton G; Viktrup L; Brown MT; West CR; Verburg KM
Arthritis Res Ther; 2022 Mar; 24(1):78. PubMed ID: 35351194
[TBL] [Abstract][Full Text] [Related]
19. Current Models for Development of Disease-Modifying Osteoarthritis Drugs.
Makarczyk MJ; Gao Q; He Y; Li Z; Gold MS; Hochberg MC; Bunnell BA; Tuan RS; Goodman SB; Lin H
Tissue Eng Part C Methods; 2021 Feb; 27(2):124-138. PubMed ID: 33403944
[TBL] [Abstract][Full Text] [Related]
20. [A multi-center cross-sectional survey of medicine application in patients with osteoarthritis in China].
Zhang XY; Peng JJ; Liu CH; Cai XY; Zhang JL; Mei YF; Jin HT; Wang XF; Mo H; Li ZG
Beijing Da Xue Xue Bao Yi Xue Ban; 2018 Dec; 50(6):1044-1048. PubMed ID: 30562779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
